



Press Release

TrovaGene announces that its NPM1 technology is now part of LabCorp's and InVivoScribe Technologies' AML cancer testing services

San Diego, Calif., March 24, 2010 - TrovaGene, Inc. (TROV.PK), formerly Xenomics, Inc. (XNOM.PK), a developer of transrenal molecular diagnostics, announced today that LabCorp, one of the world's leading reference laboratories, (LabCorp, NYSE:LH), and InVivoScribe Technologies, a world leader in molecular hematopathology testing, have notified the Company that they have begun laboratory testing services for the detection of NPM1 mutations for the diagnosis of acute myelogenous leukemia (AML). TrovaGene has sublicensed the technology to these labs and will receive royalties based upon their testing revenue.

"We are pleased that these two companies have begun offering this valuable new testing service based on our patented NPM1 technology," said Bruce A. Huebner, TrovaGene's President and CEO. "These new tests are expected to improve patient outcomes by helping to monitor effective treatment decisions."

Acute myelogenous leukemia is a cancer of the bone marrow in which the rapid proliferation of abnormal cells interferes with normal blood cell production. There are over 13,000 new cases of AML each year in the US and 200,000 new cases worldwide. It is the deadliest form of leukemia causing more than 9,000 deaths per year in the US. The nucleophosmin protein mutation is found in approximately 35% of AML diagnosed patients and occurs in 50-60% of AML patients with normal karyotypes. The NPM1 mutation status is associated with good disease prognosis and may influence treatment options. This testing is now included in the recommendations of the National Comprehensive Cancer Network's (NCCN) Clinical Practice Guidelines in Oncology. The NPM1 mutation is also used as a patient-specific biomarker for monitoring minimal residual disease (MRD) and early detection of recurrence after treatment.

About TrovaGene, Inc.

With its headquarters and product development in San Diego, California, TrovaGene has focused on development of tests using its patented transrenal nucleic acid technology. Transrenal DNA (Tr-DNA) and RNA (Tr-RNA) are short nucleic acid fragments from normal cell death that cross the kidney barrier and can be detected in urine. Safe and simple urine collection and analysis can replace biopsy or blood sampling and has a broad range of applications, including tumor detection and monitoring, infectious disease detection, prenatal testing, tissue transplantation, genetic testing for forensic identity determination, and testing associated with drug development. The TrovaGene molecular diagnostics assays will provide information that will enable physicians to provide personalized medical care for their patients.

TrovaGene has a dominant patent position as it relates to transrenal molecular testing. It has issued U.S. and European patents that cover any and all testing for molecular targets that pass through the kidney. In addition to these core patents it has numerous patent applications pending in the areas of cancer, infectious diseases, transplantation, prenatal and genetic testing. This patent position rivals the importance of the Roche PCR and Gen-Probe ribosomal RNA patents in the molecular diagnostic field.



Statements about TrovaGene's expectations, applications of its technology, markets, and other statements that are not historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on management's current beliefs, assumptions, estimates and projections. Actual results may differ materially from those projected in the forward-looking statements for various reasons, including risks associated with product development, government regulation, market acceptance, and dependence on key personnel, obtaining financing and other factors.

TrovaGene, Inc. Contact · Bruce A. Huebner · President & CEO · 858-217-4838 x101

TrovaGene Website · <http://www.trovagene.com>